162 related articles for article (PubMed ID: 31903098)
1. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V; Ricciardi GRR; Giuffrida D; Scandurra G; Russo A; Blasi L; Spadaro P; Iacono C; Soto Parra HJ; Savarino A; Ferraú F; Zerilli F; Verderame F; Butera A; Santangelo C; Franchina V; Caruso M
Ther Adv Med Oncol; 2019; 11():1758835919895755. PubMed ID: 31903098
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui X; Liang X; Li H
Cancer Med; 2023 Aug; 12(16):16793-16804. PubMed ID: 37403746
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
4. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
5. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
6. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Hardy-Bessard AC; Brocard F; Clatot F; Lortholary A; You B; Grenier J; Martin-Babau J; Lucas B; Meunier J; Ferrero JM; Savoye AM; Marti A; Despax R; Moullet I; Emile G
Breast; 2020 Dec; 54():256-263. PubMed ID: 33188992
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Zhao Y; Xie N; Li W; Chen W; Lv Z; Zheng Y; Sun T; Liu J; Zhang J; Hu S; Wang Y; Gong C; Li Y; Xie Y; Ge R; Xu F; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211030210. PubMed ID: 34290830
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
10. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Takashima T; Tokunaga S; Tei S; Nishimura S; Kawajiri H; Kashiwagi S; Yamagata S; Noda S; Nishimori T; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K
Springerplus; 2016; 5():164. PubMed ID: 27026861
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
12. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.
De Luca R; Alù M; Genova G; Grassadonia A; Cicero G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12727-12734. PubMed ID: 33378020
[TBL] [Abstract][Full Text] [Related]
13. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
[No Abstract] [Full Text] [Related]
14. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
Mougalian SS; Kish JK; Zhang J; Liassou D; Feinberg BA
Adv Ther; 2021 May; 38(5):2213-2225. PubMed ID: 33491157
[TBL] [Abstract][Full Text] [Related]
15. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Orditura M; Gravina A; Riccardi F; Diana A; Mocerino C; Leopaldi L; Fabozzi A; Giordano G; Nettuno R; Incoronato P; Barzelloni ML; Caputo R; Pisano A; Grimaldi G; Genua G; Montesarchio V; Barbato E; Iodice G; Lieto E; Procaccini E; Mabilia R; Febbraro A; Laurentiis M; Ciardiello F
ESMO Open; 2017; 2(2):e000176. PubMed ID: 28761747
[TBL] [Abstract][Full Text] [Related]
16. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
Watanabe J
Springerplus; 2015; 4():625. PubMed ID: 26543760
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
18. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.
Garrone O; Montemurro F; Saggia C; La Verde N; Vandone AM; Airoldi M; De Conciliis E; Donadio M; Lucio F; Polimeni MA; Oletti MV; Giacobino A; Merlano MC
Springerplus; 2016; 5():59. PubMed ID: 26835238
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
